| [1] |
Lu S, Yu Y, Yang Y. Retrospect and prospect for lung cancer in China: clinical advances of immune checkpoint inhibitors[J]. Oncologist, 2019,24(Suppl 1):S21-S30. DOI: 10.1634/theoncologist.2019-IO-S1-s02.
doi: 10.1634/theoncologist.2019-IO-S1-s02
pmid: 30819828
|
| [2] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492.
doi: 10.3322/caac.21492
pmid: 30207593
|
| [3] |
段建春, 吴梅娜, 赵军, 等. 培美曲塞联合铂类药物一线治疗晚期非小细胞肺癌的疗效及预测因素分析[J]. 中华结核和呼吸杂志, 2012,35(2):97-101. DOI: 10.3760/cma.j.issn.1001-0939.2012.02.008.
doi: 10.3760/cma.j.issn.1001-0939.2012.02.008
|
| [4] |
Jiang SY, Zhang J, Wang MZ, et al. Small-cell lung cancer transformation in patients with pulmonary denocarcinoma: a case report and review of literature[J]. Medicine Baltimore, 2016,95(6):e2752. DOI: 10.1097/MD.0000000000002752.
doi: 10.1097/MD.0000000000002752
pmid: 26871823
|
| [5] |
Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations[J]. Cancer Res, 2008, 68(22): 9479-9487. DOI: 10.1158/0008-5472.CAN-08-1643.
doi: 10.1158/0008-5472.CAN-08-1643
pmid: 19010923
|
| [6] |
Oser MG, Niederst MJ, Sequist LV, et al. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin[J]. Lancet Oncol, 2015,16(4):e165-e172. DOI: 10.1016/S1470-2045(14)71180-5.
doi: 10.1016/S1470-2045(14)71180-5
pmid: 25846096
|
| [7] |
Mainardi S, Mijimolle N, Francoz S, et al. Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma[J]. Proc Natl Acad Sci U S A, 2014,111(1):255-260. DOI: 10.1073/pnas.1320383110.
doi: 10.1073/pnas.1320383110
pmid: 24367082
|
| [8] |
Sutherland KD, Song JY, Kwon MC, et al. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma[J]. Proc Natl Acad Sci U S A, 2014,111(13):4952-4957. DOI: 10.1073/pnas.1319963111.
doi: 10.1073/pnas.1319963111
|
| [9] |
Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J]. Sci Signal, 2013,6(269): p l1. DOI: 10.1126/scisignal.2004088.
|
| [10] |
Tan HL, Sood A, Rahimi HA, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma[J]. Clin Cancer Res, 2014,20(4):890-903. DOI: 10.1158/1078-0432.CCR-13-1982.
doi: 10.1158/1078-0432.CCR-13-1982
pmid: 24323898
|
| [11] |
Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo clinic experience[J]. Cancer, 2005,103(6):1172-1178. DOI: 10.1002/cncr.20903.
doi: 10.1002/cncr.20903
pmid: 15700264
|
| [12] |
Jacks T, Fazeli A, Schmitt EM, et al. Effects of an Rb mutation in the mouse[J]. Nature, 1992,359(6393):295-300. DOI: 10.1038/359295a0.
doi: 10.1038/359295a0
pmid: 1406933
|
| [13] |
Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer[J]. Nat Commun, 2015,6:6377. DOI: 10.1038/ncomms7377.
doi: 10.1038/ncomms7377
pmid: 25758528
|
| [14] |
Meder L, König K, Ozreti'c L, et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas[J]. Int J Cancer, 2016,138(4):927-938. DOI: 10.1002/ijc.29835.
doi: 10.1002/ijc.29835
pmid: 26340530
|
| [15] |
Zakowski MF, Ladanyi M, Kris MG, et al. EGFR mutations in small-cell lung cancers in patients who have never smoked[J]. N Engl J Med, 2006,355(2):213-215. DOI: 10.1056/NEJMc053610.
pmid: 16837691
|
| [16] |
Desai TJ, Brownfield DG, Krasnow MA. Alveolar progenitor and stem cells in lung development, renewal and cancer[J]. Nature, 2014,507(7491):190-194. DOI: 10.1038/nature12930.
pmid: 24499815
|
| [17] |
Miettinen PJ, Warburton D, Bu D, et al. Impaired lung branching morphogenesis in the absence of functional EGF receptor[J]. Dev Biol, 1997,186(2):224-236. DOI: 10.1006/dbio.1997.8593.
doi: 10.1006/dbio.1997.8593
pmid: 9205141
|
| [18] |
Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors[J]. Sci Transl Med, 2011,3(75):75ra26. DOI: 10.1126/scitranslmed.3002003.
doi: 10.1126/scitranslmed.3002003
pmid: 21430269
|
